{"id":"https://openalex.org/W7224088997","doi":"https://doi.org/10.3389/fphar.2026.2026318","title":"Editorial: Cancer and cardiovascular diseases: common mechanisms and strategies of prevention","display_name":"Editorial: Cancer and cardiovascular diseases: common mechanisms and strategies of prevention","publication_year":2026,"publication_date":"2026-10-28","ids":{"openalex":"https://openalex.org/W7224088997","doi":"https://doi.org/10.3389/fphar.2026.2026318"},"language":"en","primary_location":{"id":"doi:10.3389/fphar.2026.2026318","doi":"https://doi.org/10.3389/fphar.2026.2026318","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.2026318","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.2026318/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"volume":null,"type":"editorial","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.2026318/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5071758568","display_name":"Paola Patrignani","orcid":"https://orcid.org/0000-0003-1419-2691","observed_orcids":["https://orcid.org/0000-0003-1419-2691"]},"institutions":[{"id":"https://openalex.org/I19630809","display_name":"Mario Negri Institute for Pharmacological Research","ror":"https://ror.org/05aspc753","country_code":"IT","type":"nonprofit","lineage":["https://openalex.org/I19630809","https://openalex.org/I4210110338","https://openalex.org/I4210153126"]},{"id":"https://openalex.org/I39387349","display_name":"University of Chieti-Pescara","ror":"https://ror.org/00qjgza05","country_code":"IT","type":"education","lineage":["https://openalex.org/I39387349"]}],"countries":["IT"],"is_corresponding":true,"raw_author_name":"Paola Patrignani","raw_affiliation_strings":["Department of Neuroscience, Imaging and Clinical Sciences, \u201cG. d\u2019Annunzio\u201d University","Department of experimental oncology Mario Negri Institute for Pharmacological Research (IRCCS)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neuroscience, Imaging and Clinical Sciences, \u201cG. d\u2019Annunzio\u201d University","institution_ids":["https://openalex.org/I39387349"]},{"raw_affiliation_string":"Department of experimental oncology Mario Negri Institute for Pharmacological Research (IRCCS)","institution_ids":["https://openalex.org/I19630809"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089202679","display_name":"Pietro Minuz","orcid":"https://orcid.org/0000-0001-5450-2186","observed_orcids":["https://orcid.org/0000-0001-5450-2186"]},"institutions":[{"id":"https://openalex.org/I119439378","display_name":"University of Verona","ror":"https://ror.org/039bp8j42","country_code":"IT","type":"education","lineage":["https://openalex.org/I119439378"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Pietro Minuz","raw_affiliation_strings":["Department of Medicine, University of Verona"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, University of Verona","institution_ids":["https://openalex.org/I119439378"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5082078699","display_name":"Dieter Steinhilber","orcid":"https://orcid.org/0000-0001-8905-5208","observed_orcids":["https://orcid.org/0000-0001-8905-5208"]},"institutions":[{"id":"https://openalex.org/I114090438","display_name":"Goethe University Frankfurt","ror":"https://ror.org/04cvxnb49","country_code":"DE","type":"education","lineage":["https://openalex.org/I114090438"]}],"countries":["DE"],"is_corresponding":true,"raw_author_name":"Dieter Steinhilber","raw_affiliation_strings":["Institute of Pharmaceutical Chemistry, Goethe University Frankfurt"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institute of Pharmaceutical Chemistry, Goethe University Frankfurt","institution_ids":["https://openalex.org/I114090438"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5071758568","https://openalex.org/A5082078699"],"corresponding_institution_ids":["https://openalex.org/I114090438","https://openalex.org/I19630809","https://openalex.org/I39387349"],"apc_list":{"value":3150,"currency":"CHF","value_usd":3801},"apc_paid":{"value":3150,"currency":"CHF","value_usd":3801},"fwci":null,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"17","issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.5522000193595886,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10678","display_name":"Inflammatory mediators and NSAID effects","score":0.5522000193595886,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11355","display_name":"Inflammatory Biomarkers in Disease Prognosis","score":0.17970000207424164,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12955","display_name":"Atherosclerosis and Cardiovascular Diseases","score":0.10220000147819519,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cancer","display_name":"cancer","score":0.609000027179718},{"id":"https://openalex.org/keywords/cardiovascular-disease","display_name":"cardiovascular disease","score":0.9810000061988831},{"id":"https://openalex.org/keywords/chronic-inflammation","display_name":"chronic inflammation","score":0.9850000143051147},{"id":"https://openalex.org/keywords/platelet-activation","display_name":"platelet activation","score":0.8539999723434448},{"id":"https://openalex.org/keywords/thromboxane-a2","display_name":"thromboxane A2","score":0.9769999980926514},{"id":"https://openalex.org/keywords/colorectal-cancer","display_name":"colorectal cancer","score":0.8420000076293945},{"id":"https://openalex.org/keywords/metastasis","display_name":"metastasis","score":0.7590000033378601},{"id":"https://openalex.org/keywords/low-dose-aspirin","display_name":"low-dose aspirin","score":0.875},{"id":"https://openalex.org/keywords/antiplatelet-therapy","display_name":"antiplatelet therapy","score":0.7440000176429749},{"id":"https://openalex.org/keywords/albumin","display_name":"albumin","score":0.8529999852180481},{"id":"https://openalex.org/keywords/thrombosis","display_name":"thrombosis","score":0.7609999775886536},{"id":"https://openalex.org/keywords/cancer-associated-thrombosis","display_name":"cancer-associated thrombosis","score":0.8420000076293945},{"id":"https://openalex.org/keywords/venous-thromboembolism","display_name":"venous thromboembolism","score":0.9850000143051147},{"id":"https://openalex.org/keywords/catheter-related-thrombosis","display_name":"catheter-related thrombosis","score":0.9520000219345093},{"id":"https://openalex.org/keywords/pcsk9-inhibitors","display_name":"PCSK9 inhibitors","score":0.8069999814033508},{"id":"https://openalex.org/keywords/evolocumab","display_name":"evolocumab","score":0.9890000224113464},{"id":"https://openalex.org/keywords/interleukin-1beta","display_name":"IL-1\u03b2","score":0.8339999914169312},{"id":"https://openalex.org/keywords/il-17a","display_name":"IL-17A","score":0.9890000224113464},{"id":"https://openalex.org/keywords/st-elevation-myocardial-infarction","display_name":"ST-elevation myocardial infarction","score":0.9179999828338623},{"id":"https://openalex.org/keywords/endothelial-dysfunction","display_name":"endothelial dysfunction","score":0.6589999794960022}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7759000062942505},{"id":"https://openalex.org/C2776914184","wikidata":"https://www.wikidata.org/wiki/Q101991","display_name":"Inflammation","level":2,"score":0.6220999956130981},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5835999846458435},{"id":"https://openalex.org/C3018697912","wikidata":"https://www.wikidata.org/wiki/Q179217","display_name":"Platelet activation","level":3,"score":0.5544999837875366},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.4758000075817108},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.41670000553131104},{"id":"https://openalex.org/C555283112","wikidata":"https://www.wikidata.org/wiki/Q1637543","display_name":"Carcinogenesis","level":3,"score":0.41609999537467957},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.40549999475479126},{"id":"https://openalex.org/C2777628954","wikidata":"https://www.wikidata.org/wiki/Q18216","display_name":"Aspirin","level":2,"score":0.38269999623298645},{"id":"https://openalex.org/C2778198053","wikidata":"https://www.wikidata.org/wiki/Q181754","display_name":"Heart failure","level":2,"score":0.3720000088214874},{"id":"https://openalex.org/C2779256057","wikidata":"https://www.wikidata.org/wiki/Q16909647","display_name":"Tumor progression","level":3,"score":0.3529999852180481},{"id":"https://openalex.org/C89560881","wikidata":"https://www.wikidata.org/wiki/Q101026","display_name":"Platelet","level":2,"score":0.3472000062465668},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.31349998712539673},{"id":"https://openalex.org/C89611455","wikidata":"https://www.wikidata.org/wiki/Q6804646","display_name":"Mechanism (biology)","level":2,"score":0.31060001254081726},{"id":"https://openalex.org/C2781362458","wikidata":"https://www.wikidata.org/wiki/Q1588755","display_name":"Thrombus","level":2,"score":0.3084999918937683},{"id":"https://openalex.org/C168261976","wikidata":"https://www.wikidata.org/wiki/Q5347407","display_name":"Efferocytosis","level":4,"score":0.3012000024318695},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.2985999882221222},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.2953999936580658},{"id":"https://openalex.org/C2778233292","wikidata":"https://www.wikidata.org/wiki/Q2118956","display_name":"Cardiotoxicity","level":3,"score":0.2937999963760376},{"id":"https://openalex.org/C2776992346","wikidata":"https://www.wikidata.org/wiki/Q111140","display_name":"Endothelium","level":2,"score":0.29190000891685486},{"id":"https://openalex.org/C2780394083","wikidata":"https://www.wikidata.org/wiki/Q539568","display_name":"Angiogenesis","level":2,"score":0.28940001130104065},{"id":"https://openalex.org/C2909112448","wikidata":"https://www.wikidata.org/wiki/Q721432","display_name":"Platelet aggregation inhibitor","level":3,"score":0.2838999927043915},{"id":"https://openalex.org/C2107291","wikidata":"https://www.wikidata.org/wiki/Q14886885","display_name":"Mediator","level":2,"score":0.2833000123500824},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.2831000089645386},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2824000120162964},{"id":"https://openalex.org/C63645605","wikidata":"https://www.wikidata.org/wiki/Q103191","display_name":"Homeostasis","level":2,"score":0.2777000069618225},{"id":"https://openalex.org/C2779013556","wikidata":"https://www.wikidata.org/wiki/Q181876","display_name":"Metastasis","level":3,"score":0.272599995136261},{"id":"https://openalex.org/C2776107976","wikidata":"https://www.wikidata.org/wiki/Q1786433","display_name":"Tumor microenvironment","level":3,"score":0.263700008392334},{"id":"https://openalex.org/C2780234812","wikidata":"https://www.wikidata.org/wiki/Q1787013","display_name":"Cancer prevention","level":3,"score":0.2621000111103058},{"id":"https://openalex.org/C2778163477","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Cholesterol","level":2,"score":0.2578999996185303},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.25699999928474426},{"id":"https://openalex.org/C2776335557","wikidata":"https://www.wikidata.org/wiki/Q415366","display_name":"Tirofiban","level":4,"score":0.25380000472068787},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.25040000677108765}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.3389/fphar.2026.2026318","doi":"https://doi.org/10.3389/fphar.2026.2026318","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.2026318","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.2026318/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:doaj.org/article:155a39c1e7ee48bf8f5ac2f812ecf345","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/155a39c1e7ee48bf8f5ac2f812ecf345","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Pharmacology, Vol 17 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fphar.2026.2026318","doi":"https://doi.org/10.3389/fphar.2026.2026318","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fphar.2026.2026318","pdf_url":"https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.2026318/pdf","source":{"id":"https://openalex.org/S132108250","display_name":"Frontiers in Pharmacology","issn_l":"1663-9812","issn":["1663-9812"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","ki-jl-1","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7224088997.pdf","grobid_xml":"https://content.openalex.org/works/W7224088997.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3172682710","https://openalex.org/W4405694156","https://openalex.org/W2061288397","https://openalex.org/W7159880834","https://openalex.org/W2886080841","https://openalex.org/W7167039643","https://openalex.org/W7155562570","https://openalex.org/W2919115270","https://openalex.org/W4416930468","https://openalex.org/W4378953295"],"abstract_inverted_index":{"Chronic":[0],"inflammation":[1,35],"represents":[2,628],"a":[3,96,298,638,755,848],"central":[4],"link":[5],"between":[6,177,416,597,641],"cancer":[7,342,377,418,442,531,556,583,648,721],"and":[8,18,28,42,72,88,128,154,165,181,228,231,273,317,349,368,382,406,419,425,444,449,456,480,485,489,503,521,543,584,601,624,645,678,688,701,722,730,737,798,819,835],"cardiovascular":[9,199,262,396,467,483,493,528,568,585,723,749,796,833],"disease.":[10],"Inflammatory":[11],"mediators":[12],"contribute":[13],"to":[14,39,69,242,256,261,482,538,715,824,840,853],"endothelial":[15,271],"dysfunction,":[16,401],"atherosclerosis,":[17],"adverse":[19],"cardiac":[20,408],"remodeling,":[21],"while":[22,747],"also":[23,195,564,669],"influencing":[24],"tumor":[25,83,794],"initiation,":[26],"progression,":[27,795],"interactions":[29],"with":[30,118,183,189,207,218,225,303,496,661,809],"the":[31,62,100,114,122,129,219,284,320,353,362,393,413,466,492,510,536,565,602,653,713,748],"immune":[32,500],"system.":[33],"Importantly,":[34],"is":[36,140,281,509],"closely":[37],"linked":[38],"platelet":[40,138,152,734],"activation":[41,153],"lipid":[43,657,686],"mediator":[44],"biosynthesis,":[45],"offering":[46],"potential":[47,101,184,524],"targets":[48],"for":[49,99,124,186,198,338,376,447,472,527,758,816],"interventions":[50,250,788],"that":[51,149,215,248,374,554,580,720],"address":[52,491],"both":[53,582,775],"conditions.In":[54],"this":[55,326,716],"context,":[56],"Di":[57],"Berardino":[58],"et":[59,145,212,309,332,410,432,463,516,592,635,673],"al.":[60,213,310,333,411,433,464,517,593,636],"discuss":[61,445,518],"contribution":[63],"of":[64,90,104,131,137,167,278,286,296,301,314,322,355,364,387,395,452,469,567,605,632,655,683,704,745,751,831],"platelet-derived":[65],"thromboxane":[66],"A\u2082":[67],"(TXA\u2082)":[68],"colorectal":[70,304,606],"carcinogenesis":[71],"metastasis.":[73],"Beyond":[74],"its":[75,160],"established":[76],"role":[77],"in":[78,108,237,325,341,440,530,659,692],"thrombosis,":[79,182,736],"TXA\u2082":[80],"may":[81,251,576,789],"promote":[82],"development":[84,130,604],"through":[85,157,570,727],"inflammatory":[86,258],"signaling":[87],"suppression":[89],"antitumor":[91],"immunity.":[92],"These":[93,170,398],"findings":[94,172,246,611,651,698,779],"provide":[95],"mechanistic":[97,778],"rationale":[98],"anticancer":[102,388,752],"effects":[103,468,682,792],"low-dose":[105],"aspirin,":[106],"particularly":[107,266,742],"genetically":[109],"defined":[110],"patient":[111,126,826,854],"populations.":[112],"However,":[113],"bleeding":[115,383,799],"risks":[116],"associated":[117,188,224,495],"antiplatelet":[119],"therapy":[120],"emphasize":[121,652],"need":[123,537],"careful":[125],"selection":[127],"safer":[132],"pharmacological":[133,663],"approaches.The":[134],"regulatory":[135],"complexity":[136,386,654],"function":[139,236,569],"further":[141,618,710],"illustrated":[142],"by":[143,671],"Tai":[144],"al.,":[146,674],"who":[147],"demonstrate":[148,719],"albumin":[150],"inhibits":[151],"thrombus":[155],"formation":[156],"mechanisms":[158,427,703],"involving":[159,205],"negatively":[161],"charged":[162],"surface":[163],"residues":[164],"modulation":[166],"PKC/Akt":[168],"signaling.":[169],"experimental":[171],"identify":[173,311],"an":[174,202,293,595],"additional":[175,460,507],"connection":[176],"plasma":[178],"protein":[179],"homeostasis":[180],"implications":[185],"conditions":[187],"hypoalbuminemia,":[190],"including":[191,499],"advanced":[192],"malignancy.Inflammatory":[193],"pathways":[194,667,764],"offer":[196],"opportunities":[197],"intervention.":[200],"In":[201],"observational":[203,610],"study":[204,300],"patients":[206,302,443,660],"ST-elevation":[208],"myocardial":[209,400],"infarction,":[210],"Zhang":[211],"report":[214,594],"early":[216],"treatment":[217,380,389,557],"PCSK9":[220],"inhibitor":[221],"evolocumab":[222],"was":[223],"reduced":[226],"IL-1\u03b2":[227],"IL-17A":[229],"levels":[230],"improved":[232],"left":[233],"ventricular":[234],"heart":[235,438,599],"STEMI.":[238],"Although":[239,608],"causality":[240],"remains":[241],"be":[243,290,838],"established,":[244],"these":[245,329,359,551,696],"suggest":[247,699],"lipid-modifying":[249],"extend":[252],"beyond":[253,842],"cholesterol":[254,643],"reduction":[255],"involve":[257],"processes":[259],"relevant":[260,743],"pathology.Cancer-associated":[263],"thrombosis":[264,288,316,340],"illustrates":[265],"well":[267],"how":[268],"malignancy,":[269],"inflammation,":[270],"injury,":[272,404],"coagulation":[274],"interact.":[275],"The":[276],"management":[277],"thromboembolic":[279],"complications":[280,494,529],"challenging":[282],"because":[283],"prevention":[285,357,448],"recurrent":[287,315],"must":[289],"balanced":[291],"against":[292,774],"increased":[294],"risk":[295,324,336,372,574,817],"bleeding.In":[297],"retrospective":[299],"cancer-associated":[305],"venous":[306],"thromboembolism,":[307],"Liang":[308],"clinical":[312,707,731,760,781,811],"predictors":[313],"bleeding,":[318],"emphasizing":[319,421],"heterogeneity":[321],"thrombotic":[323],"population.":[327],"Complementing":[328],"findings,":[330],"Xie":[331],"systematically":[334],"review":[335,412,465,534,677],"factors":[337,526,575],"catheter-related":[339],"patients.":[343,532],"Their":[344,533,650],"analysis":[345],"distinguishes":[346],"patient-,":[347],"catheter-,":[348],"treatment-related":[350],"determinants,":[351],"underscoring":[352],"importance":[354],"individualized":[356],"strategies.Together,":[358],"contributions":[360,714],"highlight":[361],"limitations":[363],"uniform":[365],"antithrombotic":[366],"approaches":[367,481,664],"support":[369,577,617],"more":[370,849],"precise":[371],"assessment":[373],"accounts":[375],"characteristics,":[378],"comorbidities,":[379],"exposure,":[381],"susceptibility.The":[384],"growing":[385],"has":[390,458],"substantially":[391],"expanded":[392],"spectrum":[394],"complications.":[397],"include":[399],"arrhythmias,":[402],"vascular":[403],"hypertension,":[405],"immune-mediated":[407],"damage.Liu":[409],"bidirectional":[414],"relationship":[415],"breast":[417,441],"CVD,":[420],"shared":[422,621,763],"inflammatory,":[423,623],"metabolic,":[424,622],"hormonal":[426],"alongside":[428],"treatment-associated":[429],"cardiotoxicity.":[430],"M\u0119drek":[431],"focus":[434,804],"specifically":[435],"on":[436,685,793,805],"radiation-induced":[437],"disease":[439,600],"strategies":[446,579,822],"cardioprotection.The":[450],"emergence":[451],"molecularly":[453],"targeted":[454,470],"therapies":[455,471,753],"immunotherapies":[457],"introduced":[459],"challenges.":[461],"Nardin":[462],"non-small-cell":[473],"lung":[474],"cancer,":[475],"highlighting":[476],"drug-specific":[477],"toxicity":[478],"profiles":[479],"surveillance":[484],"management.":[486],"Similarly,":[487],"Iram":[488],"Lebeche":[490],"modern":[497],"immunotherapies,":[498],"checkpoint":[501],"inhibitors":[502],"cellular":[504],"immunotherapies.An":[505],"important":[506,630],"dimension":[508],"patient's":[511],"general":[512],"physiological":[513,545],"condition.":[514],"Papasotiriou":[515],"malnutrition,":[519],"cachexia,":[520],"sarcopenia":[522],"as":[523,741],"susceptibility":[525],"highlights":[535],"consider":[539],"systemic":[540],"metabolic":[541,738],"alterations":[542],"impaired":[544],"reserve":[546],"when":[547,787],"assessing":[548],"cardiotoxicity":[549],"risk.Collectively,":[550],"articles":[552],"underline":[553],"effective":[555],"requires":[558,709,783],"not":[559,613,766],"only":[560],"oncological":[561],"efficacy":[562],"but":[563],"preservation":[566],"interdisciplinary":[571],"management.Identifying":[572],"common":[573,666],"preventive":[578,821],"benefit":[581,782],"health.":[586],"Using":[587],"UK":[588],"Biobank":[589],"data,":[590],"Geng":[591],"association":[596,640],"coronary":[598],"subsequent":[603],"polyps.":[607],"such":[609],"do":[612],"establish":[614],"causality,":[615],"they":[616],"investigation":[619],"into":[620,780],"lifestyle-related":[625],"determinants.Lipid":[626],"metabolism":[627,687],"another":[629],"area":[631],"convergence.":[633],"Hou":[634],"describe":[637],"nonlinear":[639],"LDL":[642],"concentrations":[644,658],"mortality":[646],"among":[647],"survivors.":[649],"interpreting":[656],"malignancy.Potential":[662],"targeting":[665,769],"are":[668,725],"explored":[670],"Gao":[672],"whose":[675],"systematic":[676],"meta-analysis":[679],"indicate":[680],"beneficial":[681],"flavonoids":[684],"atherosclerotic":[689],"plaque":[690],"burden":[691],"ApoE-deficient":[693],"mice.":[694],"While":[695],"preclinical":[697],"anti-inflammatory":[700],"antioxidant":[702],"interest,":[705],"their":[706],"relevance":[708],"validation.Taken":[711],"together,":[712],"Research":[717],"Topic":[718],"diseases":[724,846],"interconnected":[726],"multiple":[728],"biological":[729],"mechanisms.":[732],"Inflammation,":[733],"activation,":[735],"dysfunction":[739],"emerge":[740],"areas":[744],"convergence,":[746],"consequences":[750],"represent":[754],"major":[756],"challenge":[757],"contemporary":[759],"practice.Nevertheless,":[761],"identifying":[762,813],"does":[765],"necessarily":[767],"mean":[768],"them":[770],"will":[771,837],"simultaneously":[772],"protect":[773],"diseases.":[776],"Translating":[777],"rigorous":[784],"investigation,":[785],"especially":[786],"produce":[790],"competing":[791],"outcomes,":[797],"risk.Future":[800],"research":[801],"should":[802],"therefore":[803],"integrating":[806],"molecular":[807],"insights":[808],"prospective":[810],"studies,":[812],"reliable":[814],"biomarkers":[815],"stratification,":[818],"developing":[820],"adapted":[823],"individual":[825],"characteristics.":[827],"Ultimately,":[828],"closer":[829],"integration":[830],"oncology,":[832],"medicine,":[834],"pharmacology":[836],"essential":[839],"move":[841],"treating":[843],"two":[844],"separate":[845],"toward":[847],"comprehensive,":[850],"personalized":[851],"approach":[852],"care.":[855]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2026-10-29T00:00:00"}